Otrivine products

Go To

Multiple products
Nasal symptoms are the most bothersome symptoms of a cold^1,2
An effective active ingredient
Otrivine range of products
Otrivine Product Information

A range of products to help relieve nasal congestion symptoms

A range of nasal decongestant products developed to relieve the symptoms of acute rhinitis in cold, allergy and sinusitis.

Nasal symptoms are the most bothersome symptoms of a cold^1,2

The impacts of nasal congestion on quality of life include:

Discomfort from obstructed breathing due to swelling and mucous²
Inconvenience from the frequent need to blow the nose²
Reduced quality and quantity of sleep^3,4
Daytime fatigue and poor concentration⁴
Lost time from work or school⁵.

Otrivine Nasal Sprays and Drops contain an effective active ingredient that quickly decongests nasal passageways

Topical xylometazoline hydrochloride is a sympathomimetic active ingredient which acts locally to constrict dilated blood vessels in the nasal mucosa^6-8

Reduces swelling
Relieves nasal congestion
Facilitates sinus drainage

Recommend the Otrivine range to help patients to relieve nasal congestion symptoms

Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml Nasal Spray (xylometazoline hydrochloride, ipratropium bromide)

Dual action formulation
Relieves nasal congestion, sneezing and runny nose
One application offers lasting relief (6 hours)
Suitable for use from 18 years and older

Otrivine Sinusitis Relief 0.1% w/v Nasal Spray (Xylometazoline Hydrochloride)

Acts quickly to relieve nasal congestion associated with sinusitis.

Starts to decongest within 2 minutes, lasts for up to 10 hours
Relieves symptoms of nasal congestion in connection with common cold, perennial and allergic rhinitis and sinusitis
Suitable for use from 12 years and over

Otrivine Adult Measured Dose nasal spray pack

Otrivine Congestion Relief Menthol 0.1% w/v Nasal Spray (xylometazoline hydrochloride)

For congested individuals over 12 years old who are looking for fast and effective relief of nasal congestion. Includes menthol.

Starts to decongest within 2 minutes, lasts for up to 10 hours
Relieves symptoms of nasal congestion in connection with common cold, perennial and allergic rhinitis and sinusitis
Suitable for use from 12 years and over

Otrivine Adult nasal spray and drops packs

Otrivine Adult 0.1% w/v Nasal Drops (xylometazoline hydrochloride) and Otrivine Congestion Relief 0.1% Nasal Spray (xylometazoline hydrochloride)

A choice of spray or drop formats to relieve symptoms of nasal congestion.

Starts to decongest within 2 minutes, lasts for up to 10 hours
Relieves symptoms of nasal congestion in connection with common cold, perennial and allergic rhinitis and sinusitis
Suitable for use from 12 years and over

Otrivine Range Product Information

Product information – Otrivine Range

Product Information: Please refer to the Summary of Product Characteristics for full product information.

Otrivine Congestion Relief Menthol, 0.1%w/v Nasal Spray, Solution; Otrivine Sinusitis Relief 0.1% w/v Nasal Spray, Solution; Otrivine Adult 0.1% w/v Nasal Drops, Solution; Otrivine Congestion Relief 0.1% w/v Nasal Spray, Solution (xylometazoline hydrochloride). Indication: For the relief of nasal congestion due to colds, hay fever or other allergic rhinitis, sinusitis. Dosage and administration: Adults and adolescents over 12 years of age: Nasal Drops: 2 to 4 drops in each nostril, up to three times daily as needed. Congestion Relief Nasal Spray: 1 to 2 sprays into each nostril, up to three times daily as needed. Measured Dose Sinusitis Spray: 1 spray into each nostril, 3 times daily as needed. Congestion Relief Menthol Spray: 1 spray into each nostril, 3 times daily as needed. Do not exceed 3 applications daily into each nostril. Contraindications: Hypersensitivity to xylometazoline or to any of the excipients. Trans-sphenoidal hypophysectomy or surgery exposing the dura mater. Acute coronary disease, hyperthyroidism or narrow angle glaucoma. Treatment with monoamine oxidase inhibitors, or within 14 days of stopping such treatments. Rhinitis sicca and Atrophic rhinitis. Children aged less than 12 years old. Precautions: Use with caution in patients with hypertension, cardiovascular disease, diabetes mellitus, phaeochromocytoma, prostatic hypertrophy and in those on tri- and tetracyclic antidepressants. Do not use for more than seven consecutive days: prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa. Caution in patients with a strong reaction to adrenergic substances. Patients with long QT syndrome, due to increased risk of serious ventricular arrhythmias. Do not exceed the recommended dose especially in children and in the elderly. To prevent cross infection, each pack should be used by one person only. All, excluding PA 0678/120/005: Contains benzalkonium chloride which can cause irritation or swelling inside the nose. Congestion Relief Menthol Spray: Contains polyoxyl hydrogenated castor oil which may cause skin reactions. Side effects: See full SPC for details. Common: headache, nasal dryness and discomfort, nausea, application site burning. Uncommon: Epistaxis. Legal category: Pharmacy only. Licence number: Otrivine Congestion Relief Menthol 0.1% w/v Nasal Spray PA 0678/120/005; Otrivine Sinusitis Relief 0.1% w/v Nasal Spray PA 0678/120/003; Otrivine Adult 0.1% w/v Nasal Drops PA 0678/120/001; Otrivine Congestion Relief 0.1% w/v Nasal Spray PA 0678/120/002. Licence holder: Haleon Ireland Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Date of preparation: November 2023. Further information available on request.

Contains Xylometazoline hydrochloride. Always read the label/leaflet. Ask you pharmacist for advice.
Product information – Otrivine Extra Dual Relief

Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml nasal spray, solution (xylometazoline hydrochloride and ipratropium bromide)

Indications: Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds.Dosage and method of administration: Adults: 1 puff in each nostril up to 3 times daily. 6 hours min. between 2 doses. Max. 3 puffs daily into each nostril. Max. 7 days use. Do not exceed the stated dose. Paediatric population: Not for use under 18 years of age. Geriatrics: Limited experience of use in patients above 70 years of age. Contraindications: Hypersensitivity to ingredients, atropine or atropine like substances. After surgical operations where dura mater may have been penetrated. Patients with glaucoma, rhinitis sicca or atrophic rhinitis. Precautions: Use with caution in patients with hypertension, cardiovascular diseases, long QT syndrome, hyperthyroidism, diabetes mellitus, hypertrophy of the prostate, stenosis of the bladder bar, pheochromocytoma, cystic fibrosis, on monoamine oxidase inhibitors treatment, on tri/tetra cyclic antidepressants (or have been on either within the last two weeks), on beta 2-agonist treatment and a sensitivity to adrenergic substances. Use with caution in patients predisposed to angle closure glaucoma, epistaxis and paralytic ileus. Immediate hypersensitivity - may occur. Avoid spraying in or around the eye. Side effects: Very Common: Epistaxis. Common: nasal dryness, dysgeusia, headache, nasal discomfort, nasal congestion, dry throat, throat irritation, rhinalgia, dry mouth, dizziness, nausea, application site burn. Uncommon: insomnia, parosmia, tremor, eye irritation, dry eye, palpitations, tachycardia, nasal ulcer, dysphonia, orophyaryngeal pain, sneezing, dyspepsia, fatigue, corneal oedema, conjunctival hyperaemia, cough. See SPC for full list. Legal category: Pharmacy Only. Product Licence Number: PA 0678/131/001. MAH: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Full product information is available in the SPC. Additional information is available upon request. Text prepared: November 2023.

Ask your pharmacist for advice. Always read the label/leaflet.

Help your patients to manage their nasal congestion with Otrivine

Respiratory Health

Find out about respiratory health conditions, their impact and how your products can help your patients.

Find out more

Learning Lab

Access educational resources to build your knowledge and skills.

Access resources

Sign up for updates

For news, updates, and more, click the link below to sign up and be on our mailing list.

References

Arruda E, Pitkäranta A, Witek TJ Jr, Doyle CA, Hayden FB. Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Micro-biol. 1997; 35:2864–2868.
Graf P, Eccles R, Chen S. Efficacy and safety of intranasal xylometazoline and ipratropium in patients with common cold. Expert Opin Pharmacother.2009;10(5):889–908.
Wynne JW. Obstruction of the nose and breathing during sleep. Chest 1982;82(657):658.
Rombaux P, Liistro G, Hamoir M, et al. Nasal obstruction and its impact on sleep-related breathing disorders. Rhinology 2005; 43:242–250
Worrall G. Common cold. Can Fam Phys 2007; 53:1735–1736.
Graf P et al. Efficacy and safely of intranasal xylometazoline and ipratropium in patients with common cold. Expert Opin. Pharmacother. (2009) 10(5)
Eccles R, Eriksson M, Garreffa S, Chen S. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol 2008; 22:491–496.
Clarke RW, Cook JA. Jones AS. The effect of nasal mucosal vasoconstriction on nasal airflow sensation. Clinical Otolaryngol Allied Sci 1995; 20:72–73.

This channel is intended for Healthcare Professionals, and those working under their supervision, in the Republic of Ireland Only.

Haleon, formerly part of GSK.© 2024 GSK group of companies or its licensor. Trade marks are owned by or licensed to the Haleon group of companies. Haleon Ireland Limited is a private limited company registered in Ireland, with company number 24797 and registered office 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

PM-IE-22-00002